期刊
AMERICAN JOURNAL OF TRANSPLANTATION
卷 18, 期 9, 页码 2285-2294出版社
WILEY
DOI: 10.1111/ajt.14893
关键词
clinical research; practice; histocompatibility; lung transplantation; pulmonology; major histocompatibility complex (MHC); monitoring: immune; rejection: antibody-mediated (ABMR); rejection: T cell mediated (TCMR)
资金
- National Heart, Lung, and Blood Institute [HL 105412]
Donor-specific antibodies (DSA) to mismatched human leukocyte antigens (HLA) are associated with worse outcomes after lung transplantation. To determine the incidence and characteristics of DSA early after lung transplantation, we conducted a prospective multicenter observational study that used standardized treatment and testing protocols. Among 119 transplant recipients, 43 (36%) developed DSA: 6 (14%) developed DSA only to class I HLA, 23 (53%) developed DSA only to class II HLA, and 14 (33%) developed DSA to both class I and class II HLA. The median DSA mean fluorescence intensity (MFI) was 3197. We identified a significant association between the Lung Allocation Score and the development of DSA (HR=1.02, 95% CI: 1.001-1.03, P=.047) and a significant association between DSA with an MFI3000 and acute cellular rejection (ACR) gradeA2 (HR=2.11, 95% CI: 1.04-4.27, P=.039). However, we did not detect an association between DSA and survival. We conclude that DSA occur frequently early after lung transplantation, and most target class II HLA. DSA with an MFI3000 have a significant association with ACR. Extended follow-up is necessary to determine the impact of DSA on other important outcomes. In this prospective, multicenter, observational study, the authors report that 36% of lung transplant recipients develop donor-specific antibodies to human leukocyte antigens within 120 days of transplantation. Snyder and Tinckam's editorial is on page 2111.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据